Drugs / FF/VI
last change Aug 2024 re-read 2 minutes ago

FF/VI

Developed for
asthma
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04937387 Jul 2021 → Aug 2024 asthma GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as FF/VI ClinicalTrials.gov intervention name — accepted as the source's own label NCT04937387
Route Inhaled “FF/VI via ELLIPTA inhaler” NCT04937387